Lima, Peru — The International Society for Stem Cell Application (ISSCA) announces the ISSCA Peptide World Congress – Peru 2026, taking place on May 22–23, 2026, in Lima, Peru. This landmark international event positions Peru at the center of the global conversation on peptide-based medicine, regenerative science, and clinical innovation, reflecting the country’s growing role in advanced medical education across Latin America.
The Peptide World Congress represents a natural evolution following ISSCA’s previous presence in Peru, where the organization delivered a high-level educational event under complex operational and logistical conditions. Despite the challenges, the strong participation, engagement, and clinical outcomes demonstrated the maturity of the local medical community and its readiness for a more specialized, globally focused congress.
“Peru has demonstrated exceptional engagement and readiness for advanced medical education,” said Benito Novas, Founder of ISSCA.
“After the success of our previous experience in the country, it became clear that the next step was to host a world-class congress entirely dedicated to peptides—one of the most dynamic and transformative fields in regenerative and longevity medicine today.”
From Regional Engagement to a Global Peptide Platform
Peptide-based medicine has rapidly become a cornerstone of modern regenerative and longevity care, with clinical applications spanning metabolic regulation, immune modulation, inflammation control, musculoskeletal repair, aesthetics, and performance optimization.
ISSCA’s decision to host a Peptide World Congress in Peru reflects both the country’s increasing clinical sophistication and its strategic position as a meeting point for physicians from Latin America and the global medical community. The 2026 edition expands the scientific scope, depth of education, and international participation, positioning the event as a reference point within ISSCA’s global calendar.
A Specialized Scientific Experience Focused on Peptides
The ISSCA Peptide World Congress will feature an advanced scientific program dedicated exclusively to peptide-based therapies and their integration within regenerative and functional clinical models. Key topics include:
- Peptide signaling and cellular communication
- Clinical peptide protocols for longevity and metabolic optimization
- Musculoskeletal recovery and repair using peptide-driven strategies
- Inflammation control and immune balance
- Integration of peptides with regenerative, functional, and performance medicine
- Evidence-based implementation and clinical safety standards
This focused approach is designed to standardize, professionalize, and elevate how peptide therapies are applied across diverse clinical settings.
A Market Ready for a Specialized Global Congress
ISSCA’s return to Peru with a Peptide World Congress is a direct response to demonstrated demand. The success of prior initiatives—despite operational complexity—confirmed that the country is prepared to host high-level, globally relevant medical congresses that go beyond introductory education and move toward specialization and leadership.
The 2026 edition reflects ISSCA’s commitment to investing in regions that show sustained engagement, academic maturity, and long-term growth potential.
A Global Meeting Point for Collaboration and Growth
Beyond its scientific agenda, the Peptide World Congress will create curated environments designed to foster meaningful collaboration among physicians, faculty, and industry leaders. These interactions will encourage cross-border clinical exchange, strategic alliances, and long-term integration into ISSCA’s global medical network.
This convergence reinforces ISSCA’s role as a global platform where leaders in regenerative and peptide medicine connect, collaborate, and help shape the future of healthcare.
The ISSCA Peptide World Congress – Peru 2026 (May 22–23) represents a defining moment for the country’s medical community—transforming previous experience into a world-class, specialized international congress aligned with the future of regenerative and longevity medicine.
Physicians and healthcare professionals interested in participating can register at:
Early registration benefits include:
- Special Early-Bird pricing
- Priority access to certification programs
- Admission to MedConnect Brasil
- Pre-event educational materials and digital resources
About ISSCA
“The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.”
About Global Stem Cells Group
“Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.”
Safe Harbor Statement
Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business, partly based on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
